Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.

Shares of Marinus Pharmaceuticals, Inc. MRNS fell sharply in today’s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first quarter 2024 financial results.

Marinus Pharma reported Prelim ZTALMY (Ganaxolone) net product revenue of $7.4 million to $7.6 million for the first quarter.

Marinus Pharmaceuticals shares dipped 74.2% to $1.94in pre-market trading.

Here are some big stocks recording losses in today’s pre-market trading session.

• Neumora Therapeutics, Inc. NMRA shares declined 17.1% to $11.25 pre-market trading after the FDA placed a clinical hold on the company's Phase 1 NMRA-266 study.
• Roadzen, Inc. RDZN shares fell 14% to $5.04 in pre-market trading.
• Ultragenyx Pharmaceutical Inc. RARE shares fell 11.4% to $41.64 in pre-market trading after the company disclosed interim Phase 1/2 data in patients with angelman syndrome after treatment with GTX-102.
• Cogent Biosciences, Inc. COGT shares declined 7.7% to $6.01 in pre-market trading. Cogent Biosciences recently reported preclinical data from CNS-Penetrant ErbB2 Inhibitor Program.
• Polestar Automotive Holding UK PLC PSNY shares fell 7.2% to $1.35 in pre-market trading.
• Molina Healthcare, Inc. MOH shares fell 7.1% to $350.00 in pre-market trading.
• TORM plc TRMD shares slipped 3.1% to $32.92 in pre-market trading.

Now Read This: Top 3 Tech Stocks That May Explode This Month

Don’t forget to check out our premarket coverage here